Vertex Pharmaceuticals Analysts Increase Their Forecasts After Q4 Results
The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...
Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord
Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up from $408.Maximize Your Portfolio with Data ...
来自MSN2 小时
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...
Vertex Pharmaceuticals price target raised to $467 from $435 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...
Vertex COO Arbuckle to step down later this year
Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
Zacks.com on MSN3 小时
Can GOOGL's Cloud Investments Push the Stock Higher in 2025?
Alphabet GOOGL shares have returned 26.4% in the trailing 12-month period, outperforming the Zacks Computer & Technology ...
Markets Steady, Positive; Q4 Earnings Keep Rolling
Markets were flat but positive in an initial trading day for a new week, basically shrugging off whatever warnings signs may have been considered regarding President Trump’s 25% steel tariff headline ...
What is executive branch lobbying? How people get paid to influence KY’s top leaders
Four different Kentucky lobbyists made more than $1 million for their efforts to influence policy and government over the ...